Genes, BRCA1

"Genes, BRCA1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.

Descriptor ID	D019398
MeSH Number(s)	G05.360.340.024.340.375.249.100 G05.360.340.024.340.415.400.100
Concept/Terms	Genes, BRCA1 Genes, BRCA1 BRCA1 Genes Gene, BRCA1 BRCA1 Gene

Below are MeSH descriptors whose meaning is more general than "Genes, BRCA1".

Biological Sciences [G]
Genetic Phenomena [G05]
Genetic Structures [G05.360]
Genome [G05.360.340]
Genome Components [G05.360.340.024]
Genes [G05.360.340.024.340]
Genes, Neoplasm [G05.360.340.024.340.375]
Genes, Tumor Suppressor [G05.360.340.024.340.375.249]
Genes, BRCA1 [G05.360.340.024.340.375.249.100]
Genes, Recessive [G05.360.340.024.340.415]
Genes, Tumor Suppressor [G05.360.340.024.340.415.400]
Genes, BRCA1 [G05.360.340.024.340.415.400.100]

Below are MeSH descriptors whose meaning is related to "Genes, BRCA1".

Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA1".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Genes, BRCA1" by people in this website by year, and whether "Genes, BRCA1" was a major or minor topic of these publications.

Bar chart showing 47 publications over 22 distinct years, with a maximum of 5 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	2	2
1999	1	0	1
2000	1	0	1
2001	1	1	2
2002	1	1	2
2003	1	0	1
2004	3	2	5
2005	0	1	1
2006	1	2	3
2007	0	1	1
2008	3	1	4
2009	0	1	1
2010	2	2	4
2011	2	2	4
2012	2	0	2
2013	1	0	1
2014	2	1	3
2015	0	1	1
2016	0	2	2
2020	1	2	3
2021	0	2	2
2025	0	1	1

Below are the most recent publications written about "Genes, BRCA1" by people in Profiles.

Alvero AB, Wu S, Farrell A, Kim S, Wallbillich JJ, Winer I, Morris R, Spetzler D, Anderson ML, Puccini A, Jones NL, Herzog TJ, Thaker PH, Mor G, Gogoi RP. Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis. Gynecol Oncol. 2025 03; 194:71-79.

View in: PubMed
Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.

View in: PubMed
Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.

View in: PubMed
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, ?zg?roglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 12 10; 383(24):2345-2357.

View in: PubMed
Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole I, Broach V, Chi DS. Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation. Obstet Gynecol. 2020 06; 135(6):1270-1274.

View in: PubMed
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 05 28; 382(22):2091-2102.

View in: PubMed
Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol. 2016 Oct; 43(5):560-565.

View in: PubMed
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016 08 01; 22(15):3764-73.

View in: PubMed
Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol. 2015 Apr; 137(1):86-92.

View in: PubMed
Cho JY, Cho DY, Ahn SH, Choi SY, Shin I, Park HG, Lee JW, Kim HJ, Yu JH, Ko BS, Ku BK, Son BH. Large genomic rearrangement of BRCA1 and BRCA2 genes in familial breast cancer patients in Korea. Fam Cancer. 2014 Jun; 13(2):205-11.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement